Thu, October 26, 2017

Gena Wang Maintained (SRPT) at Hold with Increased Target to $49 on, Oct 26th, 2017

Gena Wang of Barclays, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $46 to $49 on, Oct 26th, 2017.

Gena has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Gena's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Gena


  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Monday, October 2nd, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $81 on, Thursday, September 7th, 2017